May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Bevacizumab for the Treatment of Macular Edema Resulting From Idiopathic Parafoveal Telangectasia
Author Affiliations & Notes
  • A. R. MacDonald
    Dalhousie University, Halifax, Nova Scotia, Canada
  • P. Cheevers
    Dalhousie University, Halifax, Nova Scotia, Canada
    Department of Ophthalmology and Visual Sciences,
  • A. Samad
    Dalhousie University, Halifax, Nova Scotia, Canada
    Department of Ophthalmology and Visual Sciences,
  • Footnotes
    Commercial Relationships  A.R. MacDonald, None; P. Cheevers, None; A. Samad, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2720. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. R. MacDonald, P. Cheevers, A. Samad; Intravitreal Bevacizumab for the Treatment of Macular Edema Resulting From Idiopathic Parafoveal Telangectasia. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2720. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the safety and efficacy of intravitreal bevacizumab (Avastin®, Genentech) in the treatment of macular edema resulting from idiopathic parafoveal telangectasia (IPT).

Methods: : A retrospective study involving 6 eyes of 6 patients, 4 females and 2 males, with a mean age of 70.8 years (range: 56-86), with macular edema secondary to IPT. No previous treatment had been administered to these patients including laser therapy or intravitreal triamcinolone acetonide. Patients underwent three intravitreal injections of Bevacizumab 1.25mg at 6 week intervals. Baseline assessment included best corrected visual acuity (BCVA), intravenous fluorescein angiography (IVF), foveal thickness and macular volume as determined by optical coherence tomography (OCT). These parameters were reassessed at 18 weeks.

Results: : Mean BCVA was 0.37 +/-.13 LogMAR (range: 0.2 â€" 0.54) at baseline and increased to .30 +/- .19 LogMAR (range: 0 - 0.5) at 18 weeks (p = 0.15). Mean foveal thickness was 231.6 +/- 65.7u at baseline and decreased to 219.7 +/- 47.7u at 18 weeks. (p = 0. 21) Mean total macular volume decreased from 6.88+/- 0.55 mm3 at baseline to 6.72 +/- 0.39 mm3 at 18 weeks. (p = 0.05) No adverse events were observed, including inflammation, endophthalmitis, elevated intraocular pressure, retinal detachments or thromboembolic phenomenon. Microvascular leakage as determined by IVF was reduced from baseline in all patients.

Keywords: vascular endothelial growth factor • retinal neovascularization • macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×